Authors: Daniel, DG Potkin, SG Reeves, KR Swift, RH Harrigan, EP

Citation: Dg. Daniel et al., Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: a double-blind, randomized trial, PSYCHOPHAR, 155(2), 2001, pp. 128-134

Authors: Keck, PE Reeves, KR Harrigan, EP

Citation: Pe. Keck et al., Ziprasidone in the short-term treatment of patients with schizoaffective disorder: Results from two double-blind, placebo-controlled, multicenter studies, J CL PSYCH, 21(1), 2001, pp. 27-35

Authors: Fontaine, KR Heo, M Harrigan, EP Shear, CL Lakshminarayanan, M Casey, DE Allison, DB

Citation: Kr. Fontaine et al., Estimating the consequences of anti-psychotic induced weight gain on health and mortality rate, PSYCHIAT R, 101(3), 2001, pp. 277-288

Authors: Lesem, MD Zajecka, JM Swift, RH Reeves, KR Harrigan, EP

Citation: Md. Lesem et al., Intramuscular ziprasidone, 2 mg versus 10 mg, in the short-term managementof agitated psychotic patients, J CLIN PSY, 62(1), 2001, pp. 12-18

Authors: Bednar, MM Harrigan, EP Anziano, RJ Camm, AJ Ruskin, JN

Citation: Mm. Bednar et al., The QT interval, PROG CARD, 43(5), 2001, pp. 1-45

Authors: Daniel, DG Zimbroff, DL Potkin, SG Reeves, KR Harrigan, EP Lakshminarayanan, M

Citation: Dg. Daniel et al., Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: A 6-week placebo-controlled trial, NEUROPSYCH, 20(5), 1999, pp. 491-505